Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study
Titel:
Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study
Auteur:
Gadgeel, Shirish M Gandhi, Leena Riely, Gregory J Chiappori, Alberto A West, Howard L Azada, Michele C Morcos, Peter N Lee, Ruey-Min Garcia, Linta Yu, Li Boisserie, Frederic Di Laurenzio, Laura Golding, Sophie Sato, Jotaro Yokoyama, Shumpei Tanaka, Tomohiro Ou, Sai-Hong Ignatius